Epigallocatechin-3-gallate ameliorates LPS-induced ARDS by modulating Akkermansia-associated SCFAs metabolism and inhibiting the JAK2/STAT3 candidate signaling pathway - PubMed
2 days ago
- #gut-lung axis
- #EGCG
- #ARDS
- Epigallocatechin-3-gallate (EGCG) reduces inflammation and tissue damage in LPS-induced ARDS.
- EGCG modulates gut microbiota, increasing Akkermansia muciniphila (AKK) abundance.
- AKK-derived short-chain fatty acids (SCFAs) inhibit the JAK2/STAT3 signaling pathway.
- SCFAs from gut microbiota reach the lungs, suppressing systemic inflammation.
- Fecal microbiota transplantation (FMT) and AKK transplantation validate EGCG's therapeutic effects.
- EGCG offers a novel gut microbiota-based approach for ARDS treatment.